BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL.

B Introduction: b Individualized, PET2-guided first-line treatment of patients with advanced-stage classical Hodgkin Lymphoma (AS-cHL) with eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) achieves outstanding survival outcomes, but also causes relevant treatment-related morbidity (TRMB). This mature and unparalleled PFS rate suggests that individualized treatment with PET2-directed BrECADD is currently the most effective therapy for adult patients with AS-cHL. BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. [Extracted from the article]